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Abstract
How do organisms sense the amount of oxygen in the environment and respond appropriately when 
the level of oxygen decreases? Oxygen sensing and the molecular stratagems underlying the process 
have been the focus of an endless number of investigations trying to find an answer to the question: 
"What is the identity of the oxygen sensor?" Dynamic changes in pO2 constitute a potential signaling 
mechanism for the regulation of the expression and activation of reduction-oxidation (redox)-sensitive 
and oxygen-responsive transcription factors, apoptosis-signaling molecules and inflammatory 
cytokines. The transition from placental to lung-based respiration causes a relatively hyperoxic shift or 
oxidative stress, which the perinatal, developing lung experiences during birth. This variation in ∆pO2, 
in particular, differentially regulates the compartmentalization and functioning of the transcription 
factors hypoxia-inducible factor-1α (HIF-1α) and nuclear factor-κB (NF-κB). In addition, oxygen-evoked 
regulation of HIF-1α and NF-κB is closely coupled with the intracellular redox state, such that 
modulating redox equilibrium affects their responsiveness at the molecular level (expression/
transactivation). The differential regulation of HIF-1α and NF-κB  in vitro is paralleled by oxygen-
sensitive and redox-dependent pathways governing the regulation of these factors during the transition 
from placental to lung-based respiration ex utero. The birth transition period in vivo and ex utero also 
regulates apoptosis signaling pathways in a redox-dependent manner, consistent with NF-κB being 
transcriptionally regulated in order to play an anti-apoptotic function. An association is established 
between oxidative stress conditions and the augmentation of an inflammatory state in pathophysiology, 
regulated by the oxygen- and redox-sensitive pleiotropic cytokines.
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Introduction
Living aerobic organisms, from prokaryotes to complex eu-
karyotes, have developed elaborate sequences of adaptive 
mechanisms to maintain oxygen homeostasis and equilibri-
um [1–3]. In mammals, for instance, the development of the 
respiratory and cardiovascular systems allows the acquisi-
tion and appropriate distribution of oxygen as a substrate 
for oxidative phosphorylation, the major biochemical reac-
tion for the derivation of ATP (the vital biological currency 
necessary to maintain cell survival) [3,4]. As the terminal 
electron acceptor for oxidative phosphorylation, molecular 
oxygen occupies an essential role in many of the metabolic 
processes associated with aerobic existence [1–4]. The 
process of breathing is the initial step of respiration, which 
includes both the movement of oxygen from the lungs to the 
tissues and the process of cellular respiration that gener-
ates ATP [4].
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The role of the lung in adult life is essentially one of gas ex-
change. This is an organ responsible for providing a moist 
epithelial barrier for the transport of atmospheric oxygen 
into the blood via a network of fine capillaries enveloping 
the alveolar sacs, while concomitantly removing from the 
body the accumulating waste, CO2[5–7]. The cone-
shaped lungs are divided into lobes, each of which is sub-
divided into lobules having bronchioles that serve many al-
veoli. Each alveolar sac is made up of simple squamous 
epithelium surrounded by blood capillaries, thereby allow-
ing for efficient and rapid gas exchange across this barrier 
[5–8]. The development of a mature lung, therefore, is cru-
cial for survival; within the context of an integral physiologi-
cal system, tightly regulating the partial pressure of oxygen 
(pO2) is important in the face of a continuously changing 
environment [4–10].
The airway epithelium, in particular, is not only an inert bar-
rier but also a major participant in signaling mechanisms 
during development and under pathophysiological condi-
tions [5–7,11–15]. Therefore, any damage caused to the 
airway epithelium can adversely affect its normal physiology 
and regulatory processes [6,7]. The major functions of the 
airway epithelium include the following: i) it is a dynamic 
physiological barrier to diffusion and osmotic processes; ii) 
it provides an integral metabolic function by synthesizing 
and degrading chemical components either endogenously 
produced or exogenously introduced; and iii) it possesses 
a secretory property in that the epithelium has an inherent 
capacity to produce mucus, cytokines and chemokines, 
hormones, growth factors and enzymes [6,7,11–15]. This 
underlines the significance of a physiologically competent 
epithelium, because metabolic failure or noxious damage 
would lead to abnormalities in the normal development and 
functioning of the lung [11–15].
The transition from placental to lung-based respiration 
causes a relatively hyperoxic shift or oxidative stress, which 
the perinatal, developing lung experiences during birth 
[5,10,12–14]. Dynamic changes in pO2, therefore, consti-
tute a potential signaling mechanism for the regulation of 
the expression and activation of redox-sensitive transcrip-
tion factors, apoptosis signaling and proinflammatory cy-
tokines [13,14,16–18]. This review is primarily concerned 
with discussing the recent understanding of redox signal-
ing and gene regulation, the role of oxygenation in deter-
mining cell fate (apoptosis) and the downstream, 
protracted inflammatory state.
Lung maturation: an overview of prenatal and 
postnatal developmental stages
The development of the human lung begins on approxi-
mately the 26th day of gestation (4 weeks after concep-
tion). Lung maturation continues postnatally and is not 
completed until late childhood (up to 8 years), although 
postnatal development generally consists of an increase in 
the number of mature alveoli [5,8]. The major stages of lung 
development, going from a glandular structure to an alveo-
lar structure capable of efficient gaseous exchange with the 
capillary network, begin at the eighth week of gestation and 
continue to term (40 weeks) and postnatally [5]. The 32 
weeks of gestational development are classified into stag-
es in accordance with the visual appearance of lung tissue: 
embryonic, pseudoglandular, canalicular, saccular, and al-
veolar.
Embryonic stage
The embryonic stage of lung development (26 days  6 
weeks) begins when the respiratory diverticulum, or lung 
bud, appears as an outgrowth from the ventral wall of the 
foregut. This stage is followed by the separation of the lung 
bud from the foregut, thus forming the trachea (windpipe) 
and bronchial buds, which successively enlarge at the be-
ginning of the fifth week to form the main bronchi. The em-
bryonic stage is marked by the formation of the lobular and 
segmental sections of the respiratory tree as columnar-
epithelium-lined tubes evident by the end of the fifth or sixth 
week [5].
Pseudoglandular stage
The pseudoglandular stage roughly begins at the fifth/sixth 
week of gestation and lasts up until 16th/17th week. What 
marks this period are the histological appearance of the 
fetal lungs as an exocrine gland and the completion of the 
proliferation of the primitive airways. At this stage, cartilage 
is formed around the larger airways and smooth muscles 
begin to envelop airways and blood vessels. Upon comple-
tion of this stage, acinar outlines first begin to appear as ep-
ithelial tubes continue to grow and branch. The 
undifferentiated columnar epithelial cells lining the tubular 
glandular structures are destined to evolve into the many 
cell types that populate the airways, including serous, gob-
let, ciliated, Clara and alveolar cells [5,6,8].
Canalicular stage
The canalicular development stage comprises the period 
commencing on the 16th/17th week and continuing to the 
25th-27th weeks of gestation. The enlargement of the lumi-
na of bronchi and terminal bronchioles characterizes the 
canalicular stage, in addition to the formation of capillaries 
at the site of the future air space and the appearance of sur-
factant, representing the major developments that are ab-
solutely crucial to extra-uterine life. During this stage, in 
addition, the acini subdivisions are formed, and the epithe-
lial lining begins to differentiate into alveolar type I (ATI) and 
II (ATII) cells [5,6].
Saccular stage
The saccular stage, or terminal sac stage (28th-35th week 
of gestation), represents the development of terminal air 
sacs from alveolar ducts, refinement of gas exchange sites, Available online http://respiratory-research.com/content/3/1/26
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a decrease in the thickness of the interstitium, thinning of 
the epithelium and separation of the terminal air units. This 
stage also marks the terminal differentiation stages of alve-
olar ATI and ATII epithelial cells.
Alveolar stage
The final 5 weeks of fetal lung development, termed the al-
veolar period, encompass the alveolar stage in which mil-
lions of alveoli are formed, with the surface area increased 
by thinning of the septal walls and attenuation of the cuboi-
dal epithelium. The terminal subsaccules are now separat-
ed by loose connective tissue and cellular maturation 
continues specifically with ATII cells developing a greater 
density of lamellar bodies [5,6].
Differentiation of ATI and ATII cells
Concomitant with the development of various lung struc-
tures is the cellular differentiation of ATI and ATII cells oc-
curring as the alveolar epithelium matures. During the first 
four months of gestation the epithelial lining is more or less 
columnar to cuboidal [5–7]. By six months, ATI and ATII 
cells can be relatively distinguished in the more localized 
differentiated zones of pseudo-cuboidal cells.
ATI cells
ATI cells are thin, flat, squamous epithelia conspicuous be-
cause of the cells' small perinuclear body and long cyto-
plasmic extrusions; they are developed from the cuboidal 
cells that line bronchioles and cover most of the alveolar 
wall at later stages of development. ATI cells are character-
ized by having a low compliment of organelles, indicating 
low metabolic activity, thus reflecting the quiescent nature 
of these cells. The morphology of ATI cells, however, is suit-
ably convenient to provide a large surface area with a small 
volume, ideal for rapid and efficient gas exchange.
ATII cells
ATII cells are identifiable owing to their granular and cuboi-
dal appearance, as a result of the dense packing of cyto-
plasmic organelles (indicating metabolically active cells) 
and lamellar bodies, which are densely layered organelles 
that synthesize and store pulmonary surfactants [5–8]. The 
major function of a surfactant, which is a mixture of proteins 
and the lipid disaturated dipalmitoyl phosphatidylcholine, is 
to reduce the surface tension, thus facilitating lung expan-
sion during inhalation. Although ATII cells are small in diam-
eter ( 400 µm3 in rat and  900 µm3 in human), they are 
essential for proper gas exchange. Situated at the corners 
of the alveolar sacs, ATII cells represent little obstruction to 
gaseous diffusion and are fed by a capillary network. Intra-
cellularly, these cells are richly endowed with cytoplasmic 
organelles associated with the biosynthesis of surfactant 
phospholipid and related proteins. In summary, ATII cells 
function to serve as thin, gas-permeable entities for diffu-
sion and act as a protective barrier against water and elec-
trolyte leakage [5–7].
Lung responses during the transition from pla-
cental to lung-based respiration
The fetal lung develops as a fluid-filled organ and is contin-
uously situated in an environment that is relatively hypoxic 
(≤ 3% O2), which is the potential oxygen-carrying capacity 
of the umbilical vein [5,8,10,13]. When ex utero respiration 
commences, most of the lung fluid is reabsorbed into blood 
and lymph capillaries, allowing the newborn to breathe 
normally. Postnatal lung development continues and the 
50 million alveoli at birth, which have a surface area of 3–4 
m2, represent  15–20% of the 300 million alveoli present 
in the adult lung (surface area  75–100 m2) [5]. At birth, 
the lung undergoes a dramatic change from a fluid-filled to 
a gas-filled organ, thereby subjecting the neonate's lung to 
a transition from a relatively hypoxic environment to one that 
is hyperoxic (10–15% O2) [5,8,10,19,20].
The transition from placental to lung-based respiration is 
perceived as normal in fully mature babies; in contrast, pre-
term infants may suffer tremendously as the lungs may be 
insufficiently developed, and may be incapable of sustain-
ing normal breathing [8,10,13,15]. The preterm neonate 
can suffer from a variety of clinical illnesses and may devel-
op chronic lung diseases caused by the supplementation 
of exogenous oxygen [5,8,10,15]. The transition from pla-
cental to lung-based respiration, therefore, constitutes a 
potential signaling mechanism for the continuation of lung 
development and maturation while the lung experiences 
dramatic and dynamic variations in pO2[5,8,10,15,20].
During normal breathing, the incomplete reduction of 
inhaled oxygen may lead to accumulation of toxic reactive 
oxygen species (ROS) that may contribute to capillary inju-
ry and lung tissue perturbations [8,21–25]. All forms of aer-
obic life are thus faced with the threat of oxidation from 
atmospheric molecular oxygen and have developed elabo-
rate mechanisms of antioxidant defenses to cope with this 
potential problem [2,3,16–18,22,26]. Any deviation from 
homeostasis, or physiological changes in pO2, is recog-
nized as an exposure to oxidative stress [1–3,16–18,27–
31]. In particular, key developmental changes in the late-
gestation (preterm) lung have evolved to allow production 
of surfactants and enzymatic and non-enzymatic antioxi-
dants in preparation for the first breaths at birth 
[5,8,10,21,32]. Moreover, the maturation chronology of the 
lung antioxidant system parallels that of the prenatal matu-
ration of the surfactant system, highlighting the stages de-
veloping fetuses undergo in order to prepare for birth into 
an oxygen-rich environment [5,8,10,20]. Apparently, any 
perturbations in maintaining homeostatic mechanisms in 
response to changes in oxygen levels are critical in deter-
mining cellular characteristic integrity. The clinical, bio-
chemical and histologic responses of the lungs to such Respiratory Research   Vol 3 No 1   Haddad 
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variations consequently characterize the efficiency and 
specificity of the antioxidant system in combating stress 
[5,8,10,16–18]. For example, in certain lung pathophysio-
logical conditions, oxygenation of terminal airways be-
comes uneven, such that this temporal and spatial variance 
in oxygen abundance essentially determines the survival of 
the lung cells via oxygen-dependent activation of cell regu-
lators and genes critical to defending their structural/func-
tional characteristics [5,8,10,13,14,16–18,21–23,26,27].
Oxygen homeostasis and adaptation mecha-
nisms: implications for oxidative stress and 
pathophysiology
Oxidative stress
Accumulating evidence in recent years has linked the 
pathogenesis of some human diseases to increased oxida-
tive stress [5,8,15,22,27,33–36]. In particular, ROS, which 
are partially reduced metabolites of oxygen consumption, 
may contribute to alveolar-capillary membrane 
disturbances and the development of lung injury 
[5,8,10,22,35]. A wealth of data has drawn attention to 
both the significance of maintaining reducing conditions in 
cells and the fight against the damaging effect of ROS in-
termediates [17,22,35,37–39]. Oxidants, for instance, can 
cause carcinogenesis, sclerosis, Alzheimer's disease and 
other neurological disorders, acute lung injury and chronic 
lung diseases [5,8,17,22,27,33,37,38]. Oxidative cell inju-
ry involves the modification of cellular macromolecules by 
ROS, often leading to cell death and the lysis of sensitive 
cells, resulting in microvascular and alveolar perturbations 
[5,8,17,22,38,39]. Oxidative stress appears to increase in 
the lung, the level of antioxidants in some experimental 
models, and hypoxia and hyperoxia modulate fetal lung 
growth [14,16,17,21,23,27]. Furthermore, there is growing 
evidence supporting the concept of cross-talk between ox-
idative stress and upregulation of a proinflammatory signal 
through the participation of cytokines [34–36,39–44].
Cytokines
Cytokines are peptide hormones that participate in auto-
crine and paracrine signaling [42,43,45,46]. They are 
major participants in the pathophysiology of respiratory dis-
tress and have been recognized as signaling molecules re-
sponsive to dynamic variation in pO2[34,35,39–42,44]. 
Examples of such cytokines are interleukin (IL)-1β, IL-6, IL-
8, tumor necrosis factor (TNF)-α, transforming growth 
factor, and granulocyte-macrophage colony-stimulating 
factor. Cytokines and other inflammatory mediators play im-
portant (not necessarily inflammation-related) roles not only 
during fetal life, but also in the initiation of labor and in neo-
natal immunity and diseases [36–38,40,42,45,46]. Hemat-
opoietic growth factors, for example, regulate the 
maturation of progenitors in fetal and neonatal hematopoi-
etic organs [36,42,45]. Cytokines act as extrahematopoiet-
ic growth factors and as modulators of fetomaternal 
tolerance and are involved in selective apoptosis during tis-
sue remodeling [34,36–38]. Inter-regulation of cytokine 
networks is therefore critical for normal function and matu-
ration of neonatal host defenses. Neonates initially depend 
on natural (innate) immunity and antigen-specific immunity 
develops later in life [36,42,45,46]. Cytokines regulate in-
nate immunity and connect it with antigen-specific adaptive 
immunity [34,36,45,46]. This integral association between 
oxidative stress and a proinflammatory state may affect cel-
lular redox equilibrium, thereby imposing a direct role in 
modulating the pattern of gene expression in lung tissues; 
accordingly, this could be pivotal in determining cellular 
fate under these conditions [2,3,13,14,16–
19,26,27,34,39–46].
Antioxidants
As the fetus leaves the hypoxic environment and enters the 
relatively hyperoxic environment during the transition from 
placental to lung-based respiration, it is imperative that it 
develops antioxidant mechanisms to guard against the po-
tential harm posed by oxygen-derived species 
[13,14,19,20]. Defense mechanisms include, for example, 
the reduction of ROS by antioxidant enzymes such as cat-
alase, manganese-, copper- and zinc-containing superox-
ide dismutase (Mn-SOD/Cu-SOD/Zn-SOD), and the 
redox-sensitive enzyme glutathione peroxidase [2,3,13,16–
19,27,37]. ROS may not, however, pose a real threat to the 
fetus if these endproducts are detoxified and balanced 
against the amount of ROS generated [22,27,37,38,40].
In keeping with this idea, the tripeptide L-γ-glutamyl-L-
cysteinyl-glycine, or glutathione (GSH), a ubiquitous thiol, 
plays an important role in maintaining intracellular redox 
equilibrium and has evolved as one of the major detoxifying 
antioxidants and abundant thiols in almost all mammalian 
cells [13,14,40,41,47–50]. Glutathione determines intrac-
ellular redox potential and detoxifies harmful ROS by the 
glutathione-peroxidase-coupled reaction (Fig. 1). Oxygen 
signaling across membranes of intercellular compartments 
may be linked to a certain redox state that might be crucial 
in regulating the magnitude and pattern of gene expression 
of oxygen- and redox-responsive transcription factors 
[2,3,13,14,16–19]. Such transcription factors are 
implicated in determining cellular responses under both 
physiological and pathophysiological conditions [2,3,16–
18,27,37,51].
Redox-sensitive transcription factors are therefore likely to 
be differentially regulated by oxygen availability, to bind 
specific DNA consensus sequences and to activate the ex-
pression of several genes, particularly those controlling 
adaptive homeostasis in a hostile environment [2,3,16–
18,51]. Among such factors, HIF-1α and NF-κB, whose ac-
tivation states are differentially regulated under oxidative 
stress [52–55] are particularly important. HIF-1α, first iden-
tified in vitro through its DNA-binding activity expressed Available online http://respiratory-research.com/content/3/1/26
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under hypoxic conditions [56] has its concentration and ac-
tivity increased exponentially when oxygen tensions are 
decreased over physiologically relevant ranges [51–53]. 
The ubiquitous activation of HIF-1α is thus consistent with 
the significant role that this factor plays in coordinating 
adaptive responses to hypoxia [52,53]. NF-κB, on the other 
hand, was first identified as a transcription factor that regu-
lates antibody release in B cells [57]. It is central to the reg-
ulation and expression of stress-response genes in the face 
of inflammatory and oxidative challenge [13,14,16–
19,27,54,55,58]. Oxygen and redox regulation of HIF-1α
and NF-κB will be comprehensively discussed after a brief 
discussion of the regulation of oxygen-sensing mecha-
nisms.
The regulation of oxygen sensing mechanisms
Oxygen sensing and its underlying molecular stratagems 
have been the focus of experimental investigations trying to 
find an answer to the question: "What is the identity of the 
oxygen sensor?" [1–3,29–31,59–63]. The first molecular 
mechanism to be proposed to underlie oxygen sensing in 
mammalian cells involves an oxygen sensor that is a heme 
protein [1–3,59–61]. Studies on erythropoietin (EPO), a 
glycoprotein hormone required for the proliferation and dif-
Figure 1
The schematic of the redox cycle shows the relationship between antioxidant enzymes and glutathione. All enzymes are shown in green, substrates 
and products in blue, and inhibitors in red. Glutathione (GSH) is synthesized from amino acids by the action of γ-glutamylcysteine synthetase (γ-
GCS), the rate-limiting enzyme, and glutamyl synthase (GS). This reaction requires energy, is ATP-limited and is specifically inhibited at the level of γ-
GCS by L-buthionine-(S,R)-sulfoximine (BSO). GSH undergoes the glutathione-peroxidase (GSH-PX) coupled reaction, thereby detoxifying reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2). A major source of H2O2 is the biochemical conversion of superoxide anion (O2
-•) by the 
action of superoxide dismutase (SOD). During this reaction, GSH is oxidized to generate GSSG, which is recycled back to GSH by the action of 
glutathione reductase (GSSG-RD) at the expense of reduced nicotinamide (NADPH/H+), thus forming the redox cycle. The reduction of the glutath-
ione pathway is blocked by the action of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU). The major source of NADPH/H+ comes from the conversion 
of glucose, a reaction blocked by dehydroepiandrosterone (DHEA).Respiratory Research   Vol 3 No 1   Haddad 
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ferentiation of erythroid cells, demonstrated that EPO pro-
duction is enhanced under hypoxic conditions 
[52,53,59,61,64,65]. EPO expression can be induced by 
transition metals such as cobalt (Co2+) and nickel (Ni2+), 
supporting the hypothesis that these metal atoms can sub-
stitute for the iron atom within the heme moiety, and that the 
oxygen sensor for the induction of EPO is a heme protein 
[59–61,64,65]. Further evidence supporting the notion 
that the oxygen sensor is a heme protein came with addi-
tional studies that utilized carbon monoxide (CO); CO can 
noncovalently bind to ferrous (Fe2+) heme groups in hemo-
globin, myoglobin, cytochromes and other heme proteins 
[59–63] where its ligation state is structurally identical to 
that of oxygen. It was subsequently proposed that CO 
might affect oxygen sensing by locking the sensor in an oxy 
conformation, which could involve a multisubunit mecha-
nism [59–65] (Fig. 2).
Potential involvement of a microsomal mixed-function 
oxidase
In addition to the aforementioned models for oxygen sens-
ing, certain pharmacological studies, led by Fandrey and 
colleagues [66] suggest that the oxygen sensor might in-
volve a microsomal mixed-function oxidase. Based on these 
studies, it was proposed that oxygen sensing for EPO in-
volves an interaction between cytochrome P450 and cyto-
chrome P450 reductase, thereby allowing the conversion 
of molecular oxygen to superoxide anion (O2
-•) and hydro-
Figure 2
Proposed oxygen-sensing mechanisms for the regulation of gene transcription and the involvement of HIF-1 as a hypoxia-mediated transcription fac-
tor. See main text for further details. The thick 'down' arrows indicate a reduction in the amount of the molecule shown. [AQ18] CO might affect oxy-
gen sensing by locking the sensor (shown as Oxy/De-oxy in the plasma membrane and the inset) in an oxy conformation. Co2+/Ni2+ might affect 
oxygen sensing by locking the sensor in a de-oxy conformation. AA, arachidonic acid; ARNT, aryl hydrocarbon receptor nuclear translocator; CREB, 
cAMP-responsive element binding protein; CBP, CREB-binding protein; DAG, diacyl glycerol; ECF, extracellular fluid; HIF-1, hypoxia-inducible fac-
tor-1; ICF, intracellular fluid; IP3, inositol triphosphate; MAPK, mitogen-activated protein kinase; O2
-•, superoxide anion; P, phosphorylation; PKC, 
protein kinase C; ROS, reactive oxygen species; SAPK, stress-activated protein kinase; T0.5, half-life.Available online http://respiratory-research.com/content/3/1/26
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gen peroxide (H2O2) radicals [59,61,66,67]. Acker [59] 
has provided support based on spectroscopic evidence for 
the central role of an oxidase in oxygen sensing. It was re-
ported that b-cytochrome functions as a NAD(P)H oxidase, 
converting oxygen to O2
-•. The enzymatic complex in mam-
malian cells is membrane-bound and transduces the con-
version of molecular oxygen to ROS, according to the 
following equations:
CytFe2+ + O2 → CytFe2+O2
CytFe2+O2 → CytFe3+ + O2
-•
CytFe3+ + NAD(P)H → CytFe2+ + NAD(P)+
Potential involvement of the mitochondria
A resurgence of interest in mitochondrial physiology has re-
cently developed as a result of new experimental data dem-
onstrating that mitochondria function as important 
participants in a diverse collection of novel intracellular sig-
naling pathways. Further experiments showed a potential 
involvement of the mitochondria in oxygen sensing [68]. For 
instance, a spectroscopic photolysis with monochromatic 
light has identified a CO-binding heme protein falling within 
the spectrum of the mitochondrial cytochrome a3[69]. It 
was consequently proposed that this heme protein, pre-
sumably located on the plasma membrane, has a low affin-
ity for oxygen and a relatively high affinity for CO (Fig. 2). 
The same model predicted that another heme protein in the 
mitochondria has a relatively higher affinity for oxygen and 
a lower affinity for CO [59–70]. The biochemical reaction, 
which was proposed as an alternative way of regenerating 
ferroheme in the oxygen sensor, is given below:
CO + 2Fe3+ + H2O → CO2 + 2Fe2+ + 2H+
These aforementioned observations pertaining to the mito-
chondrion as a possible oxygen sensor were unequivocally 
supported by novel studies recently reported by Schu-
macker, Chandel and colleagues [71–76]. Cardiomyo-
cytes are known to suppress contraction and oxygen 
consumption during hypoxia [71]. Cytochrome oxidase un-
dergoes a decrease in Vmax during hypoxia, which could 
alter mitochondrial redox status and increase generation of 
ROS. Duranteau and colleagues [71] tested whether ROS 
generated by mitochondria act as second messengers in 
the signaling pathway linking the detection of oxygen with 
the functional response. Contracting cardiomyocytes were 
superfused under controlled oxygen conditions while fluo-
rescence imaging of 2,7-dichlorofluorescein was used to 
assess ROS generation. Compared with normoxia, graded 
increases in 2,7-dichlorofluorescein fluorescence were 
seen during hypoxia. In addition, the antioxidants 2-mercap-
topropionyl glycine and 1,10-phenanthroline attenuated 
these increases and abolished the inhibition of contraction. 
Superfusion of normoxic cells with H2O2 mimicked the ef-
fects of hypoxia by eliciting decreases in contraction that 
were reversible. To test the role of cytochrome oxidase, so-
dium azide was added during normoxia to reduce the Vmax
of the enzyme. It was observed that azide produced graded 
increases in ROS signaling, accompanied by graded de-
creases in contraction that were reversible, demonstrating 
that mitochondria respond to graded hypoxia by increasing 
the generation of ROS and suggesting that cytochrome ox-
idase may contribute to this oxygen sensing mechanism 
[71].
The same group also recently reported that mitochondrial 
ROS trigger hypoxia-induced transcription. Chandel et 
al.[72] tested whether mitochondria act as oxygen sensors 
during hypoxia and whether hypoxia and CO activate tran-
scription by increasing generation of ROS. Results showed 
that wild-type Hep3B cells increased ROS generation dur-
ing hypoxia or CoCl2 incubation. Hep3B cells depleted of 
mitochondrial DNA (ρ0 cells) failed to respire, failed to ac-
tivate mRNA for EPO, glycolytic enzymes or vascular en-
dothelial growth factor (VEGF) during hypoxia and failed to 
increase ROS generation during hypoxia. The ρ0 cells in-
creased ROS generation in response to CoCl2 and re-
tained the ability to induce expression of these genes. The 
antioxidants pyrrolidine dithiocarbamate (PDTC) and ebse-
len, a glutathione peroxidase mimetic, abolished transcrip-
tional activation of these genes during hypoxia or CoCl2 in 
wild-type cells and abolished the response to CoCl2 in ρ0
cells [72]. It was proposed that hypoxia activates transcrip-
tion via a mitochondria-dependent signaling process involv-
ing increased ROS, whereas CoCl2 activates transcription 
by stimulating ROS generation via a mitochondria-
independent mechanism [72–74].
In another interesting observation, Chandel and colleagues 
reported that mitochondrial ROS play a major role in HIF-
1α regulation [75]. In this respect, it was observed that hy-
poxia increased mitochondrial ROS generation at Complex 
III, which caused the accumulation of HIF-1α protein re-
sponsible for initiating expression of a luciferase reporter 
construct under the control of a hypoxic response element 
[75]. Of note, this response was lost in cells depleted of mi-
tochondrial DNA. Furthermore, overexpression of catalase 
abolished expression of the hypoxic response element-luci-
ferase construct during hypoxia. In addition, exogenous 
H2O2 stabilized HIF-1α protein during normoxia and acti-
vated luciferase expression in wild type and ρ0 cells. In fact, 
isolated mitochondria increased ROS generation during 
hypoxia, indicating that mitochondria-derived ROS are both 
required and sufficient to initiate HIF-1α stabilization during 
hypoxia, thereby implicating this transcription factor as a 
possible oxygen sensor (see below) [70–76].Respiratory Research   Vol 3 No 1   Haddad 
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A nonmitochondrial oxygen sensor
A nonmitochondrial oxygen sensor has, however, been re-
cently proposed. Ehleben and colleagues applied biophys-
ical methods like light absorption spectrophotometry of 
cytochromes, determination of NAD(P)H-dependent O2
-• 
formation and localization of •OH by three-dimensional 
(3D) confocal laser scanning microscopy to reveal putative 
members of the oxygen sensing signal pathway leading to 
enhanced gene expression under hypoxia [4,77]. A cell 
membrane localized nonmitochondrial cytochrome b558 
seemed to be involved as an oxygen sensor in the hepato-
ma cell line HepG2 in cooperation with the mitochondrial 
cytochrome b563, probably probing additional metabolic 
changes. The hydroxyl radical (•OH), a putative second 
messenger of the oxygen-sensing pathway generated by a 
Fenton reaction, could be visualized in the perinuclear 
space of the three human cell lines used.
Substances like cobalt or the iron chelator desferrioxamine, 
which have been applied in HepG2 cells to mimic hypoxia-
induced gene expression, interact on various sides of the 
oxygen-sensing pathway, confirming the importance of b-
type cytochromes and the Fenton reaction. Furthermore, 
NADPH oxidase isoforms with different gp91 phox 
subunits, as well as an unusual cytochrome aa3 with a 
heme:aa3 ratio of 9:91, have been discussed as putative 
oxygen sensor proteins influencing gene expression and 
ion channel conductivity [78]. ROS are believed to be im-
portant second messengers of the oxygen-sensing signal 
cascade determining the stability of transcription factors or 
the gating of ion channels. The formation of ROS by a peri-
nuclear Fenton reaction was imaged by one- and two-pho-
ton confocal microscopy, revealing both mitochondrial and 
nonmitochondrial generation.
The carotid body response to oxygen
In reference to the aforementioned observation [78] some 
recent concepts on oxygen sensing mechanisms at the ca-
rotid body chemoreceptors have been highlighted [1,79]. 
Most available evidence suggested that glomus (type I) 
cells are the initial sites of transduction and they release 
transmitters in response to hypoxia, which in turn depolar-
ize the nearby afferent nerve ending, leading to an increase 
in sensory discharge. Two main hypotheses have been ad-
vanced to explain the initiation of the transduction process 
that triggers transmitter release. One hypothesis assumed 
that a biochemical event associated with a heme protein 
triggers the transduction cascade. Supporting this idea, it 
has been shown that hypoxia might affect mitochondrial cy-
tochromes. In addition, there was a body of evidence impli-
cating nonmitochondrial enzymes such as NADPH 
oxidases, nitric oxide (NO) synthases and heme 
oxygenases located in glomus cells [79]. These proteins 
could contribute to transduction via generation of ROS, 
NO and/or CO. The other hypothesis suggested that a K+
channel protein is the oxygen sensor and inhibition of this 
channel and the ensuing depolarization is the initial event in 
transduction, as indicated by Peers and Kemp [1].
Several oxygen-sensitive K+ channels have been identified. 
Their roles in the initiation of the transduction cascade and/
or in cell excitability remain unclear. In addition, recent stud-
ies indicated that molecular oxygen and a variety of neuro-
transmitters might also modulate Ca2+ channels [79]. Most 
importantly, it is possible that the carotid body response to 
oxygen requires multiple sensors, and they work together to 
shape the overall sensory response of the carotid body 
over a wide range of arterial oxygen tensions.
The hypothesis that there exists a specific oxygen sen-
sor(s), which relay(s) chemical signals intracellularly, is con-
sistent with the notion that there is a unifying mechanism 
involved in transducing dynamic changes in pO2 to the nu-
cleus [70]. In response to ∆pO2, there is a coordinate ex-
pression of genes needed to confer appropriate responses 
to hypoxia or hyperoxia [2,3,13,14,16–19,26,27,52–55]. 
The regulation of physiologically important oxygen-respon-
sive and redox-sensitive genes would, therefore, dictate 
well controlled responses of the cell within a challenging 
environment and necessarily would determine the specifici-
ty of cellular adaptation [1–3,16–20,28,29,59–61,70–79].
Oxygen responsiveness of regulatory transcrip-
tion factors: molecular aspects
How do organisms sense the amount of oxygen in the en-
vironment and respond appropriately when the amount of 
oxygen decreases (a condition called hypoxia)? The ex-
pression of genes is predominantly determined by condi-
tions of the cellular microenvironment [2,3,16–
20,27,28,34,51,58]. Prime examples of such regulation are 
found in embryonic development of all multicellular organ-
isms. The naturally occurring regulating agents, for exam-
ple, interact with specific receptors, which subsequently 
transduce a signal into the nucleus for the regulation of 
gene expression and activation. The putative oxygen sensor 
responds to dynamic variation in pO2 such as those occur-
ring during the birth transition period [1–3,16–
20,19,20,59,61,70–79]. Upon ligand binding, this presum-
ably membrane-bound receptor transduces intracellular 
chemical/redox signals that relay messages for the regula-
tion of gene expression, a phenomenon mainly involving the 
activation of transcription factors [2,13,14,16–
18,26,34,51,70].
Oxygen homeostasis and HIF-1α regulation
In order to maintain oxygen homeostasis, a process that is, 
of course, essential for survival, pO2 delivery to the mito-
chondrial electron transport chain must be tightly main-
tained within a narrow physiological range [2,3,28,34,70]. 
This system may fail with subsequent induction of hypoxia, 
resulting either in a failure to generate sufficient ATP to sus-Available online http://respiratory-research.com/content/3/1/26
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tain metabolic activities or in a hyperoxic condition that con-
tributes to the generation of ROS, which, in excess, could 
be cytotoxic and often cytocidal [5,8,22,34]. Adaptive re-
sponses to hypoxia involve the regulation of gene expres-
sion by HIF-1α, the expression, stability and transcriptional 
activity of which increase exponentially on lowering 
pO2[52,53,56,80,81].
HIF-1α is a mammalian transcription factor expressed 
uniquely in response to physiologically relevant hypoxic 
conditions [52,53,56,64,67,70–81]. Studies of the EPO 
gene led to the identification of a cis-acting hypoxia-re-
sponse element (HRE) in its 3'-flanking region 
[52,53,67,80,81] and HIF-1 was identified through its hy-
poxia-inducible HRE-binding activity [56]. The HIF-1 bind-
ing site was subsequently used for purification of the HIF-
1α and HIF-1β subunits by DNA affinity chromatography. 
Both HIF-1 subunits are basic helix-loop-helix PAS (an ac-
ronym for the first three family members, namely Per/ARNT/
Sim) proteins: HIF-1α is a novel protein; HIF-1β is identical 
to the aryl hydrocarbon receptor nuclear translocator pro-
tein. HIF-1α DNA-binding activity and HIF-1α protein ex-
pression are rapidly induced by hypoxia and the magnitude 
of the response is inversely related to 
pO2[52,53,56,64,67,70–83].
In hypoxia, multiple systemic responses are induced, in-
cluding angiogenesis, erythropoiesis and glycolysis 
[52,53,56,71–73]. HREs containing functionally essential 
HIF-1-binding sites are identified in genes encoding VEGF, 
glucose transporter 1, and the glycolytic enzymes aldolase 
A, enolase 1, lactate dehydrogenase A and phosphoglycer-
ate kinase 1 [51–53,64,65,72,73]. HIF-1α is an important 
mediator for increasing the efficiency of oxygen delivery 
through EPO and VEGF [52,53]. A well-controlled process 
of adaptation to hypoxia enables oxygen to be delivered 
more efficiently, through upregulation of EPO and VEGF 
and the expression and activation of glucose transporters 
and glycolytic enzymes [52,53,64,65]. EPO is responsible 
for increasing blood oxygen-carrying capacity by stimulat-
ing erythropoiesis; VEGF is a transcriptional regulator of 
vascularization; and glucose transporters and glycolytic en-
zymes increase the efficiency of anaerobic generation of 
ATP [51–53].
HIF-1α has also been shown to activate transcription of 
genes encoding inducible nitric oxide synthase and heme 
oxygenase-1 (which are responsible for the synthesis of the 
vasoactive molecules NO and CO, respectively), as well as 
the gene encoding transferrin (which, like EPO, is essential 
for erythropoiesis) [52,53]. Each of these genes contains 
an HRE sequence of <100 base pairs that includes one or 
more HIF-1-binding sites containing the core sequence 5'-
RCGTG-3' [51–53]. It is expected that any reduction of tis-
sue oxygenation in vivo and in vitro would therefore provide 
a mechanistic stimulus for a graded and adaptive response 
mediated by HIF-1α. Hypoxia signal transduction is sche-
matized in Fig. 3 and the array of proteins encoded by 
genes directly controlled by HIF-1α is given in Table 1.
The von Hippel-Lindau tumor-suppressor protein
Several major molecular mechanisms that regulate HIF-1 
have recently emerged to shed a thorough light on the role 
of this transcription factor in oxygen sensing [83,84]. The 
von Hippel-Lindau tumor-suppressor protein (pVHL) has 
emerged as a key factor in cellular responses to oxygen 
availability, being required for the oxygen-dependent prote-
olysis of the α subunits of HIF (Fig. 4) [83–87]. Mutations 
in VHL cause a hereditary cancer syndrome associated 
with dysregulated angiogenesis and upregulation of hypox-
ia inducible genes [84].
Figure 3
Hypoxia signal transduction. Reduction of cellular O2 concentration 
('down' arrow) is associated with redox changes (∆) that lead to altered 
(∆) phosphorylation of HIF-1α, which increases its stability and tran-
scriptional activity, resulting in the induction of downstream gene 
expression. Putative inducers (horizontal arrows) and inhibitors 
(blocked arrows) of different stages in the proposed pathway are indi-
cated. Genistein is an inhibitor of tyrosine protein kinase and competi-
tive inhibitor of ATP in other protein kinase reactions; NaF is a non-
specific kinase inhibitor; v-Src is the viral analogue of the mammalian G-
coupled protein kinase; MG-132 is a proteasome complex inhibitor.Respiratory Research   Vol 3 No 1   Haddad 
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Recently, Ratcliffe and colleagues unequivocally elaborat-
ed on the mechanisms underlying these processes and 
showed that extracts from VHL-deficient renal carcinoma 
cells have a defect in HIF-1α ubiquitination activity, which 
was complemented by exogenous pVHL [81–84]. This de-
fect was specific for HIF-1α among a range of substrates 
tested. Furthermore, HIF-1α subunits were the only pVHL-
associated proteasomal substrates identified by compari-
son of metabolically labeled anti-pVHL immunoprecipitates 
from proteosomally inhibited cells and normal cells.
Analysis of pVHL/HIF-1α interactions defined short se-
quences of conserved residues within the internal transac-
tivation domains of HIF-1α molecules sufficient for 
recognition by pVHL. In contrast, while full-length pVHL 
and the p19 variant interact with HIF-1α, the association 
was abrogated by further N-terminal and C-terminal trunca-
tions. The interaction was also disrupted by tumor-associ-
ated mutations in the β-domain of pVHL and loss of 
interaction was associated with defective HIF-1α ubiquiti-
nation and regulation, defining a mechanism by which 
these mutations generate a constitutively hypoxic pattern of 
gene expression promoting angiogenesis [84–87]. These 
findings clearly indicate that pVHL regulates HIF-1α prote-
olysis by acting as the recognition component of a ubiquitin 
ligase complex and support a model in which its β-domain 
interacts with short recognition sequences in the α subu-
nits. Moreover, in oxygenated and iron-replete cells, HIF-1α
subunits were rapidly destroyed by a mechanism that in-
volved ubiquitination by the pVHL E3 ligase complex 
(pVHLE3) [88]. This process was suppressed by hypoxia 
and iron chelation, allowing transcriptional activation.
HIF-α proline hydroxylation
Jaakkola and colleagues [88] recently indicated that the in-
teraction between human pVHL and a specific domain of 
the HIF-1α subunit is regulated through hydroxylation of a 
proline residue (HIF-1α Pro564) by an enzyme termed by 
the authors HIF-α prolyl-hydroxylase (HIF-PH). An absolute 
requirement for oxygen as a cosubstrate and iron as a co-
factor suggested that HIF-PH functions directly as a cellu-
lar oxygen sensor. Furthermore, Masson et al.[89] recently 
identified two independent regions within the HIF-α oxy-
gen-dependent degradation domain, which are targeted for 
ubiquitination by pVHLE3 in a manner dependent upon 
Table 1 
Proteins encoded by genes directly targeted by HIF-1α
Role Protein
Glucose/energy metabolism Cell prolifer-
ation/viability
Adenylate kinase 3
Aldolase a
Aldolase c
Enolase-1
Glucose transporter 1
Glucose transporter 3
Glyceraldehyde-3-phos-
phate dehydrogenase
Hexokinase 1
Hexokinase 2
Insulin-like growth factor 
(IGF)-2
IGF-binding protein 
(IGFBP)-1
IGFBP-3
Lactate dehydrogenase a
Phosphoglycerate kinase 1
Pyruvate kinase m
p21
Transforming growth factor
Erythropoiesis Iron metabolism Ceruloplasmin
Erythropoietin
Transferring
Transferrin receptor
Vascular development/remodelling Vaso-
motor tone
Adrenergic receptor
Adrenomedullin
Endothelin-1
Heme oxygenase-1
Nitric oxide synthase 2
Plasminogen activator 
inhibitor 1
Vascular endothelial 
growth factor (VEGF)
VEGF receptor FLT-1
Figure 4
Potential oxygen-sensing mechanisms and the role of the transcription 
factor HIF. This schematic shows the role of von Hippel-Lindau tumor-
suppressor protein (shown as VHL) in mediating the regulation of HIF. It 
has emerged as a key factor in cellular responses to oxygen availability, 
being required for the oxygen-dependent proteolysis of the α subunits 
of HIF. The gray box indicates the reaction mechanisms involving the 
putative oxygen sensor. FADH, flavin adenine dinucleotide (reduced 
form); FAD, flavin adenine dinucleotide (oxidized form); 6PG, 6-phos-
phoglycerate; G6P, glucose-6-phosphate.Available online http://respiratory-research.com/content/3/1/26
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prolyl hydroxylation (Fig. 5). In a series of in vitro and in vivo
assays, Masson and colleagues demonstrated the inde-
pendent and nonredundant operation of each site in regu-
lation of the HIF system. Both sites contain a common core 
motif, but differ both in overall sequence and in the condi-
tions under which they bind to the pVHLE3 ligase complex 
[89]. The definition of two independent destruction do-
mains implicated a more complex system of pVHL-HIF-α in-
teractions, but reinforced the role of prolyl hydroxylation as 
an oxygen-dependent destruction signal.
These mechanisms were also reported in lower inverte-
brates as potential pathways for HIF oxygen sensing. For in-
stance, Epstein and colleagues [90] defined a conserved 
HIF-pVHL-prolyl hydroxylase pathway in Caenorhabditis el-
egans and used a genetic approach to identify EGL-9 as a 
dioxygenase that regulates HIF by prolyl hydroxylation. In 
mammalian cells, it was shown that the HIF-prolyl hydroxy-
lases were represented by a series of isoforms bearing a 
conserved 2-histidine-1-carboxylate-iron coordination motif 
at the catalytic site. Direct modulation of recombinant en-
zyme activity by graded hypoxia, iron chelation and cobal-
tous ions mirrored the characteristics of HIF induction in 
vivo, thereby fulfilling requirements for these HIF-prolyl hy-
droxylases to be oxygen sensors that regulate this tran-
scription factor [91–94].
Bruick and McKnight [95] reported that the inappropriate 
accumulation of HIF caused by forced expression of the 
HIF-1α subunit under normoxic conditions was attenuated 
by co-expression of HIF-PH. Suppression of HIF-PH in cul-
tured Drosophila melanogaster cells by RNA interference 
resulted in elevated expression of a hypoxia-inducible gene 
(encoding lactate dehydrogenase) under normoxic condi-
tions, indicating that HIF-PH is an essential component of 
the pathway through which cells sense oxygen. In comple-
ment with the aforementioned observations, Lando and col-
leagues [96] demonstrated that the hypoxic induction of 
the C-terminal transactivation domain (CAD) of HIF occurs 
through abrogation of hydroxylation of a conserved aspar-
agine in the CAD. Inhibitors of Fe2+- and 2-oxoglutarate-
dependent dioxygenases prevented hydroxylation of the as-
paragine, thus allowing the CAD to interact with the p300 
transcription co-activator. Replacement of the conserved 
asparagine by alanine resulted in constitutive p300 interac-
tion and strong transcriptional activity. The full induction of 
HIF, therefore, might rely on the abrogation of both proline 
and asparagine hydroxylation. During normoxia, hydroxyla-
tion of these residues occurs at the oxygen-dependent 
degradation domain and CAD, respectively.
HIF-2α and HIF-3α
Recently, two oxygen-sensitive cousins of HIF-1 have been 
identified, characterized and cloned. HIF-2 and HIF-3 are 
two closely related protein complexes that are oxygen-
responsive. The cDNAs of three HIF α-subunits were 
cloned from RNA of primary rat hepatocytes by reverse 
transcriptase PCR [97]. All three cDNAs encoded func-
tionally active proteins, of 825, 874 and 662 amino acids, 
respectively. After transfection, they were able to activate 
luciferase activity of a luciferase gene construct containing 
three HIF-responsive elements. The mRNAs of the rat HIF 
α-subunits were expressed predominantly in the pe-
rivenous zone of rat liver tissue; the nuclear HIF-α proteins, 
however, did not appear to be zonated [97]. Furthermore, 
HIFs locate to HIF-binding sites (HBSs) within the HREs of 
oxygen-regulated genes [98,99]. Whereas HIF-1α is gen-
erally expressed ubiquitously, HIF-2α (EPAS) is found pri-
marily in the endothelium, similar to endothelin-1 (ET-1) and 
fms-like tyrosine kinase-1 (Flt-1), the expression of which is 
controlled by HREs.
Camenisch and colleagues [100] identified a unique se-
quence alteration in both ET-1 and Flt-1 HBSs not found in 
other HIF-1 target genes, implying that these HBSs might 
cause binding of HIF-2 rather than HIF-1. Electrophoretic 
mobility shift assays showed HIF-1 and HIF-2 DNA com-
plex formation with the unique ET-1 HBS to be about equal. 
Both DNA-binding and hypoxic activation of reporter genes 
Figure 5
The regulation of HIF by the prolyl hydroxylase (PHD) enzyme, a puta-
tive oxygen sensor. The von Hippel-Lindau gene product (pVHL) inter-
acts with HIF-1α and is required for the destruction of HIF-1α at the 
oxygen-dependent degradation domain (ODDD) under normoxic condi-
tions. The HIF-pVHL interaction depends on both oxygen and iron avail-
ability (shown as O2 and Fe). Furthermore, HIF-1α-pVHL interaction 
requires enzymatic post-translational hydroxylation of HIF-1α at a single 
proline (shown as yellow circle labeled P564-OH). This prolyl hydroxy-
lation also requires, besides oxygen and iron, a citric acid cycle interme-
diate, 2-oxoglutarate. Together with the HIF-induced activation of 
glucose- and iron-metabolism genes, hydroxylation creates a tight link 
between oxygen sensing and cellular control of metabolism. Cul-2, B, C 
and Rbx are signaling cofactors associated with VHL in the regulation 
of ODDD. Adapted from Jaakkola et al.[88].Respiratory Research   Vol 3 No 1   Haddad 
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using the ET-1 HBS was decreased compared with those 
for transferrin and erythropoietin HBSs. The Flt-1 HBS, in 
addition, was nonfunctional when assayed in isolation, sug-
gesting that additional factors are required for hypoxic up-
regulation via the reported Flt-1 HRE [100]. Interestingly, 
HIF-1 activity could be restored fully by point-mutating the 
ET-1 (but not the Flt-1) HBS, suggesting that the wild-type 
ET-1 HBS attenuates the full hypoxic response known from 
other oxygen-regulated genes [100–102].
Oxygen homeostasis and NF-κB regulation
NF-κB is an important and widely investigated dimeric tran-
scription factor that is a major participant in signaling path-
ways governing cellular responses to environmental 
stresses [13,14,19,54,55,58,103,104]. NF-κB is involved 
in the regulation of a large number of genes that control var-
ious aspects of the immune and inflammatory response. It 
is activated by a variety of stimuli ranging from cytokines, to 
various forms of radiation, to oxidative stress (such as expo-
sure to H2O2). Recent studies have advanced our under-
standing of the signal transduction pathway leading to NF-
κB activation by cytokines and will provide insights for the 
mechanism by which NF-κB is regulated by oxidative 
stress. An important question that is yet to be answered is 
whether ROS play a physiological role in NF-κB activation.
First identified as a factor which regulates the expression of 
the immunoglobulin κ light chains in B lymphocytes [57] 
NF-κB is also recognized as a sequence-specific transcrip-
tion factor involved in the activation of an exceptionally 
large number of genes in response to inflammation, viral 
and bacterial infections, and other stressful situations re-
quiring rapid reprogramming of gene expression, such as 
oxidative challenge [54,55]. In unstimulated cells under 
resting conditions (inactive state), NF-κB exists as ho-
modimers or heterodimers of members of the Rel family 
[55,56,103,104]. The dimers of NF-κB are sequestered in 
the cytosol through noncovalent interactions with inhibitory 
proteins termed IκBs [54,55,103,104]. The translocation 
and activation of NF-κB in response to various stimuli, such 
as cytokines (IL-1 and TNF-α), microbial agents (lipopoly-
saccharide-endotoxin), oxidative challenge (ROS) and irra-
diation (UV and γ-rays), are sequentially organized at the 
molecular level [54,55,104]. NF-κB activation occurs 
through the signal-induced phosphorylation of a multisubu-
nit upstream kinase, termed IκB kinase, by NF-κB inducing 
kinase [103–105]. Stimulation leads to rapid phosphoryla-
tion of IκB, thereby marking it for ubiquitinylation and ulti-
mately proteolytic degradation. IκB degradation exposes 
the nuclear localization signal on NF-κB, thus allowing the 
nuclear translocation of the subunit and activation of the 
transcription of its target genes (Fig. 6) [54,55]. The array 
of proteins encoded by genes directly controlled by NF-κB 
is given in Table 2.
IκB-independent pathways, however, have recently been 
recognized as alternative factors that regulate the activa-
tion of NF-κB. As an example, direct phosphorylation of 
RelA (p65), the major transactivating member of the κB 
family [14,19,54,55,103] has been shown to regulate NF-
κB activation in one of two of its transactivation domains 
[106]. A further mechanism was revealed for NF-κB regu-
lation with the discovery of transcription factor-IIB/D (TF-
IIB/D) and TATA-binding protein (TBP), recognized as two 
important regulators of NF-κB transcriptional activity. The 
dominant-negative form of the mitogen-activated protein ki-
nase (MAPKp38) expression vector abrogated the interac-
tion of TF-IID/TBP with a co-transfected His-p65 fusion 
protein, and selective inhibition of MAPKp38 by SB-
203580 down-regulated TF-IID/TBP in vitro[106]. Finally, 
modulation of intracellular redox equilibrium constitutes a 
potential mechanism that can manipulate and dictate the lo-
Figure 6
Rel/NF-κB signal transduction. Various extracellular signals converge 
on the activated IκB kinase complex. IκB kinase phosphorylates IκB at 
two N-terminal serines; phosphorylation signals IκB for ubiquitination 
and proteolysis in the proteasome. The NF-κB (p50-RelA in this case) 
released in this way enters the nucleus and activates gene expression. 
One NF-κB target gene (ikba) encodes IκB. The newly synthesized IκB 
can enter the nucleus, pull NF-κB off DNA, and export NF-κB back to 
its resting state in the cytoplasm. Thick lines indicate the activating 
pathway; thin lines indicate the inactivating pathway.Available online http://respiratory-research.com/content/3/1/26
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calization and activation of NF-κB 
[2,3,13,14,26,54,55,103–106]. Hyperoxia and other 
stress conditions mediating signal-transduction pathways 
involving NF-κB are depicted in a schematized model 
shown in Fig. 7.
Redox regulation of oxygen-sensitive transcrip-
tion factors
The major determinant of the redox status in mammalian 
cells is glutathione (L-γ-glutamyl-L-cysteinyl-glycine), a 
tripeptide thiol [14,18,47–50,107]. This ubiquitous non-
essential sulfhydryl amino acid plays a major role in main-
taining intracellular redox equilibrium and in regulating cel-
lular defenses augmented by oxidative stress. Synthesized 
by the action of the rate-limiting enzyme γ-glutamylcysteine 
synthetase [47–50,107,108] glutathione uniquely provides 
a functional cysteinyl moiety that is responsible for many of 
its diverse properties.
Glutathione participation in the physiology of cellular me-
tabolism reflects the importance of this molecule in intrac-
ellular functions. First, glutathione is involved in the 
detoxification of highly reactive peroxides (ROOH) by con-
jugation of electrophiles and metals through the glutath-
ione-peroxidase coupled reaction, thus acting as an 
antioxidant (Fig. 1). For example, endogenously produced 
radicals such as H2O2 are effectively reduced by the sele-
nium-dependent glutathione peroxidase in the presence of 
glutathione as a substrate. During this reaction, glutathione 
is converted into oxidized disulfide glutathione (GSSG), 
which is recycled back to two molecules of glutathione by 
GSSG reductase at the expense of NADPH/H+, thus form-
ing what is known a redox cycle (Fig. 1). Second, glutath-
ione participates in the maintenance of intracellular protein 
integrity by reducing their disulfide linkages and regulating 
their synthesis, thereby acting as an important regulator of 
cellular sulfhydryl status and redox equilibrium. Third, glu-
tathione governs signaling pathways as an immunopharma-
cological reducing thiol; it also facilitates membrane 
trafficking of reactive chemicals and, in some cases, aug-
ments the formation of essential biological mediators. 
Fourth, glutathione regulates the expression and activation 
of redox-sensitive transcription factors, whose upregulation 
is a key component of the cellular pathways activated in 
stress-evoked responses. The restitution of redox equilibri-
um in the face of an oxidative challenge, therefore, requires 
an adaptive cross-talk between signaling pathways sensing 
variations in pO2 and genetically regulated transcription 
factors [2,3,16–18,26,51]. As such, glutathione-
associated metabolism is crucial for providing an equilibri-
um interface between oxidative stress and adaptive re-
sponses of cytoprotection [13,14,19,47–50,107].
Redox regulation of HIF-1α
Antioxidant/pro-oxidant equilibrium is likely to regulate HIF-
1α redox sensitivity [13,14,51,73,109–111]. For instance, 
the cysteine residue in the CAD has been shown to be re-
dox-sensitive, thereby affecting its interaction with CREB-
binding protein/p300 co-activators. This interaction is di-
rectly regulated by redox factor-1 and thioredoxin 
[109,110]. HIF-1α ubiquitination and degradation by the 
proteasome system under normoxic conditions are also 
regulated by redox modifications of the protein 
[52,53,82,111]. Furthermore, selective inhibition of γ-
glutamylcysteine synthetase (which results in glutathione 
depletion) in the alveolar perinatal epithelium abrogated hy-
poxia-induced nuclear localization, stabilization and activa-
tion of HIF-1α [ 13,14]. It appears, therefore, that 
maintenance of glutathione equilibrium (and by inference, 
Table 2 
The array of proteins encoded by genes directly controlled by 
NF-κB
Protein type Protein
Cytokines/growth factors IL-1α
IL-1β
IL-2
IL-3
IL-6
IL-8
IL-12
TNF-α
Lymphotoxin-α
Interferon-β
Granulocyte Colony-Stimulating
Factor
Macrophage Colony-Stimulating
Factor
Granulocyte-Macrophage Colony-
Stimulating Factor
Cytokine receptors IL-2 receptor α chain
Stress proteins Serum amyloid A protein
Complement factors B, C3 and C4
α1-acid glycoprotein
Adhesion molecules Intracellular adhesion molecule-1
Vascular cell adhesion molecule-1
Mucosal addressin cell adhesion mole-
cule-1
E-selectin
Immunoregulatory mole-
cules
Immunoglobulin κ light chain
MHC class I and II
T-cell receptor α and β
β2-Microglobulin
Invariant chain
Transporter associated with antigen 
processing
Proteasome subunit
Inducible nitric oxide synthase
Inhibitory κB
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the shuttling between reduction and oxidation states) is a 
prerequisite for HIF-1α stabilization [82,109].
This assumption is reinforced by the observation that N-
acetyl-L-cysteine (NAC, an antioxidant thiol and a precursor 
for L-cysteine, the rate-limiting amino acid in the biosynthe-
sis of glutathione [14,17,112]) imposes a reducing envi-
ronment, thereby protracting HIF-1α stability in the cytosol 
and subsequently favoring its translocation and activation 
[13,14,53,54,82,111]. On the other hand, imposing an ox-
idizing environment through the rapid accumulation of 
GSSG in the nucleus adversely affects HIF-1α activation 
[13,14]. PDTC is a nonthiol antioxidant that affects redox 
potential by scavenging radical species (a reduction prop-
erty) and directly oxidizing glutathione and related thiols (an 
oxidation property) [14,79,113]. PDTC favors a GSSG/
glutathione equilibrium and subsequent stabilization of HIF-
1α protein, but fails to induce its activation. This effect is 
Figure 7
Schematic showing signal transduction pathways mediated by environmental stresses such as lipopolysaccharide (LPS), cytokines, hyperoxia and 
irradiation (UV). The transmission of the signalling cascade across the membrane (gray 'bridge' shape) is associated with the activation of upstream 
kinases. Small G- protein-coupled proteins, such as PAK and RAC, mediate the activation of MAPK kinase kinase (MEKK) or NF-κB inducing kinase 
(NIK). The pathway then bifurcates into two branches: the p38 mitogen-activated protein kinase (MAPK) pathway and the IκB/NF-κB pathway. One 
pathway activates IκB kinase (IKK), thereby leading to IκB phosphorylation/degradation and subsequently allowing NF-κB complex to translocate to 
the nucleus and promote gene expression. The other pathway involves the phosphorylation of MAPK kinase (MKK), which phosphorylates and acti-
vates MAPK (p38). This pathway is selectively blocked by the pyridinyl imidazole SB-203580. The activation of the MAPK pathway regulates the 
downstream activation of MAPK activating kinase (MAPKAP-K2), which phosphorylates the small heat-shock protein 27 (Hsp27) and activates the 
stability of transcripts of cytokines bearing the AU-rich element (ARE). The antioxidant N-acetyl-L-cysteine (NAC) provides cysteine that feeds into 
the biosynthetic machinery, allowing the formation of glutathione (GSH) by the action of the rate-limiting enzyme, γ-glutamylcysteine synthetase (γ-
GCS). The activity of γ-GCS is irreversibly blocked by L-buthionine-(S,R)-sulfoximine (BSO). GSH is broken down to cysteine by the action of γ-
glutamyl transpeptidase (γ-GT), a membrane-bound enzyme. Redox regulation of the MAPK pathway mediated by NAC is likely to implicate the 
blockading of the upstream kinase that leads to phosphorylation and activation of p38/(reactivating kinase, RK).Available online http://respiratory-research.com/content/3/1/26
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ostensibly due to the generation of thiyl radicals and 
thiuram disulfides resulting from PDTC antioxidant reac-
tions, thus leading to oxidation of glutathione [13,14,111]. 
It is very likely, therefore, that HIF-1α's oxygen responsive-
ness resides over a permissive range of antioxidant buffer-
ing capacities, with the demonstration that the antioxidant/
pro-oxidant equilibrium effectively uncouples HIF-1α activi-
ty from the normal pattern observed in response to varia-
tions in pO2 in the alveolar epithelium [13,14,82]. Redox-
mediated pathways regulating HIF-1α transduction mecha-
nisms are shown in Fig. 8.
Redox regulation of NF-κB
Redox regulation of NF-κB seems to be compartmentalized 
[13,14,19,54,55,62,113,114]. Whereas an oxidizing sig-
nal is required for the stabilization and translocation of NF-
κB subunits, intriguingly, a reduced environment is critical 
for an optimum DNA-binding activity and transactivity 
[14,54,55,113,114]. Recent evidence suggests that NF-
Figure 8
Schematic diagram of HIF-1α activation circuits and oxygen-signaling mechanisms in hypoxia. The reduction of oxidized glutathione (GSSG) forms 
reduced glutathione (2GSH), capable of inducing HIF-1α activation. GSSG recycling to GSH is blocked by 1,3- bis-(2-chloroethyl)-1-nitrosourea 
(BCNU), a specific glutathione reductase inhibitor, thus increasing intracellular [GSSG], a potent inhibitor of DNA binding. In oxidative stress, γ-
glutamylcysteine synthetase is transformed from the native, inactive form (nγ-GCS) to the active form (γ-GCS), which increases de novo synthesis of 
GSH. This pathway is blocked by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of γ-GCS, thus affecting HIF-1α activation. Reactive 
oxygen species (ROS), derived from oxygen metabolites (ROOH), tend to block the activation of HIF-1α. N-acetyl-L-cysteine (NAC), an antioxidant, 
releases this inhibitory effect by scavenging ROS. NAC, in addition, is a major precursor of GSH, a thiol antioxidant, thereby elevating [GSH] 
(↑GSH) and inducing HIF-1α activation. Pyrrolidine dithiocarbamate (PDTC) is an antioxidant; although it possesses ROS-scavenging properties, its 
ability to activate HIF-1α under reducing conditions is not established. PDTC (as a pro-oxidant), like other dithiocarbamates, lowers the GSH/GSSG 
ratio by oxidizing GSH. The elevated [GSSG] (↑GSSG) has the potential to block HIF-1α activation. Upon HIF-1α binding to the hypoxia response 
element (HRE), hypoxia-responsive genes are upregulated.Respiratory Research   Vol 3 No 1   Haddad 
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κB plays a critical role in the early events controlling the 
molecular response to ROS [54,55,58,103]. It has been 
shown, for example, that the activation of NF-κB by a variety 
of agents can be blocked by NAC, suggesting that the pro-
duction of ROS may act as a common pathway for a di-
verse range of stimuli [13,14,54,55,58,62,101,103,114–
116]. In addition, the inhibitory effects of PDTC suggest 
post-translational instability and interference with the ca-
pacity of NF-κB to bind DNA [54,55,62,103,104]. This is 
further supported by the observation that phosphorylation 
of IκB at specific serine residues can be inhibited by dithi-
ocarbamates, pointing to the possibility that NF-κB translo-
cation and subsequent activation is mediated by ROS, 
which might induce a cytosolic kinase activity 
[54,55,103,104].
There is another assumption that GSSG-mediated inhibi-
tion of NF-κB implicates the formation of an inactive NF-
κB/disulfide complex, thereby inhibiting DNA binding activ-
ity [14,16–18,54,55,62,114–116]. Although oxidizing 
conditions are necessary in the cytosol, to allow optimum 
translocation and dissociation of NF-κB from inhibitory IκB 
(resulting in activation of NF-κB), NF-κB must be main-
tained in a reduced state in the nucleus for activation to oc-
Figure 9
[AQ27] Schematic diagram of NF-κB activation circuits and oxygen-signaling mechanisms in hyperoxia. Blocking reduction of oxidized glutathione 
(GSSG) to GSH, by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), leads to increasing intracellular stores of GSSG, a potent inhibitor of NF-κB tran-
scription factor DNA binding. The pathway leading to the formation of GSH by the action of γ-glutamylcysteine synthetase (γ-GCS) is blocked by L-
buthionine-(S,R)-sulfoximine (BSO), inducing an irreversible inhibition of NF-κB activation. ROS are key components of the pathways leading to the 
activation of NF-κB, whose binding activity is obliterated by N-acetyl-L-cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC), potent scavengers 
of ROS. Although NAC elevates [GSH], it is unknown whether this mechanism induces NF-κB activation independently from the antioxidant effects 
of this inhibitor. PDTC elevates GSSG concentration by GSH oxidation, a pro-oxidant effect characteristic of dithiocarbamates, thereby mediating 
NF-κB inhibition. Upon NF-κB DNA binding, cascades of hyperoxia-responsive genes are activated, which have the potential to modulate cellular 
response to oxidative injury.Available online http://respiratory-research.com/content/3/1/26
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cur [13,14,16–19,54,55,58,62,103,104,114–116]. 
Redox-mediated pathways regulating NF-κB transduction 
mechanisms are shown in Fig. 9.
Regulation of apoptosis signaling pathways: 
morphological, biochemical and redox/ROS 
aspects
In the past few decades since the term apoptosis was 
coined [117,118] a vast quantity of work has been per-
formed in search of the cause of the phenomenon to which 
it originally alluded. It became certain that some cells were 
genetically programmed, or destined, for death during the 
normal development of multicellular organisms [118–126]. 
Thus the general model is one of intercellular signaling mol-
ecules playing on intracellular effector systems that bal-
ance the individual cell's progress to either life (survival) or 
death (apoptosis) [119–126]. Apoptosis, first identified as 
"shrinkage necrosis" [117] was originally observed in ma-
ture human/vertebrate tissues as a stochastic loss of cells 
that showed distinctive histopathic morphology and in-
duced a minor inflammatory response [118–126]. Simply, 
it was argued that the key tenets of this model state that 
there is a universal genetic program that governs cell death 
at different stages of development, that a variety of stimuli 
can elicit or activate this program, and that, even though 
many transduction mechanisms are involved, eventually ap-
optosis requires activation of a downstream convergent, fi-
nal pathway [119–126].
The distinct forms of cell death: morphological aspects
At least two distinct forms of death are known by which 
cells undergo death: the well-characterized, and usually 
rapid, necrotic tissue damage induced by trauma and nox-
ious stimuli, and the more protracted and morphologically 
distinct form of cell death that has been termed apoptosis 
[117–126].
Apoptosis is characterized by an ordered series of events 
that take place over a longer period of time than events dur-
ing necrotic cell death. In apoptosis, cells often shrink, dis-
sociate from surrounding cells and undergo cytoplasmic 
membrane blebbing, a process in which their chromo-
somes rapidly condense and aggregate around the nuclear 
periphery and small apoptotic bodies are formed. During 
apoptosis cellular organelles retain their definition for a long 
time; the nucleus in particular displays a distinctive pattern 
of heterochromatization and eventual fragmentation. In 
many (but not all) apoptotic cells, specific nucleases cleave 
the DNA of the condensed chromosomes, thereby produc-
ing a characteristic 'ladder' [123–127].
Necrotic cell death, on the other hand, is relatively quick 
and violent, characterized by the swelling of the cytoplasm, 
the rupturing of cell membranes, the dilation of the mito-
chondria and the disintegration of subcellular and nuclear 
components. Necrosis may be considered to be analogous 
to random acts of violence that culminate in murder, where-
as apoptosis is more appropriately referred to as cellular 
suicide. The cell initiates apoptotic death when it senses 
that its environment of physical state has been vigorously 
compromised; this is, indeed, the ultimate self-sacrifice 
[117–127].
The biochemistry of cell death: molecular aspects
If there is simple dichotomy in the modes of cell death, per-
haps there is more than one basic genetic program for 
death and more than one final common pathway (Fig. 10A). 
Perhaps some ligand-induced cell death results from con-
fused or inappropriate regulation of gene expression rather 
than from turning on preset genetic programs [119–126]. 
Studies of C. elegans development, for example, have con-
tributed significantly to the biomolecular understanding of 
cell death [119,120]. Genetic analysis has led to the iden-
tification of the cellular genes required for programmed cell 
death during their development. The isolation and molecu-
lar characterization of C. elegans death (ced) genes dem-
onstrated that ced-3 gene is homologous to the gene 
encoding mammalian IL-1β-converting enzyme (ICE; cas-
pase-1) [126–129]. ICE was originally isolated from mam-
malian cells as an enzyme essential for the proper 
processing and biological activation of pro-IL-1β, a cy-
tokine involved in mediating cellular inflammatory process-
es [36,40,42–46]. The expression of ced-3/ICE rapidly 
induces apoptosis, demonstrating that this gene encodes 
a cysteine protease essential for programmed cell death 
[127–129].
Many of the genes encoding ICE-like proteases, henceforth 
referred to as caspases, were isolated by molecular clon-
ing. The term caspase is based on a common nomenclature 
universally adopted: 'c' reflects a cysteine protease mech-
anism, and 'aspase' refers to the ability of these proteases 
to cleave a protein following an aspartic acid residue [127–
129]. Many of these caspases contain a conserved se-
quence, QAC(R/Q)G, required for the catalytic activity of 
these enzymes [127–130]. The activation of the caspase 
proteases has been linked to the aggregation of cell sur-
face receptors, either when receptor-sensitive target cells 
are exposed to the appropriate ligand, or when the recep-
tors self-aggregate in response to their high cell-surface 
density. A functional caspase, therefore, can be generated 
following receptor oligomerization by autocatalysis or by 
the action of another alerted caspase. Recent evidence 
suggested that caspases regulate the process of apopto-
sis by regulating additional cellular processes, such as the 
progression through the well-defined cell cycle and its reg-
ulators [126–130].
The molecular signaling factors regulating apoptosis
As noted, multicellular organisms eliminate redundant, 
damaged, or infected cells by a stereotypic program of cell Respiratory Research   Vol 3 No 1   Haddad 
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Figure 10
Diverse pathways regulating the propagation of cell death. (A) Potential pathways to apoptosis (cell suicide), or programmed cell death. (B) Oxidant 
and redox regulation of apoptosis.Available online http://respiratory-research.com/content/3/1/26
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suicide. The first mammalian regulator of apoptosis 
emerged when bcl-2, the gene activated by chromosome 
translocation in human follicular lymphoma [131] was unex-
pectedly found to permit the survival of cytokine-dependent 
hematopoietic cells, in a quiescent state in the absence of 
exogenous cytokine [132]. Ced-9 of C. elegans and the 
mammalian Bcl-2 proved to be functional and structural 
homologues and their survival function is opposed either by 
close relatives, like Bax, or by distant cousins such as the 
mammalian proteins Bik, or Nbk, and nematode Egl-1 
[127–132]. All Bcl-2 family members possess at least one 
of four conserved motifs known as Bcl-2 homology do-
mains (BH-1,-2,-3, and -4). Most prosurvival family mem-
bers, which can inhibit apoptosis in the face of a wide 
variety of cytotoxic insults, contain at least BH-1 and BH-2, 
and those most similar in structure to Bcl-2 have all four BH 
domains [127–132].
Pro-apoptotic and anti-apoptotic family members can het-
erodimerize and seemingly titrate one another's function, 
suggesting that their relative concentrations may act as a 
rheostat for the suicide programs [133]. Bcl-2 resides on 
the cytoplasmic face of the mitochondrial outer membrane, 
endoplasmic reticulum and nuclear envelope, and may reg-
ister damage to these compartments and affect their be-
havior, possibly by modifying the flux of small molecules 
and proteins [133]. On the other hand, Bax is cytosolic be-
fore an apoptotic stimulus, even though it bears a hydro-
phobic domain (like most other family members) [133]. 
Biochemical evidence suggested that the prosurvival pro-
teins might function by directly inhibiting the activity of cas-
pases, directly or indirectly preventing the release of 
cytochrome c from the mitochondria. Along with ATP, this 
may facilitate structural changes in the procaspase domain, 
allowing its cleavage and activation [127–133]. Bax, Bax-
like proteins and the antisurvival proteins may promote ap-
optosis by cleaving and activating caspases, but also can 
initiate caspase-independent death via channel-forming ac-
tivity, which could promote the mitochondrial permeability 
transition or puncture the mitochondrial outer membrane 
[134–141].
Oxygen and redox regulation of apoptosis: Involvement 
of transcription factors
ROS are generated in all aerobic cells during normal mito-
chondrial respiration, are used by specialized phagocytic 
cells to destroy invading pathogens and are byproducts of 
the intracellular metabolism of toxic drugs and their environ-
mental metabolites [2,3,16–18,26]. Incubating cells, for in-
stance, with exogenous oxidants, free radicals, or added 
redox-active compounds has been shown to trigger the ap-
optotic process [142–155]. It has been hypothesized that 
the oxidation of cellular molecules could trigger a general 
protection alert system, and these sensors, in turn, detect 
and assess the damage, subsequently activating the apop-
totic machinery. A classic example of this model is p53-
mediated detection of DNA damage [156–159]. Alterna-
tively, low-level oxidative stress is known to activate differ-
ent protein cascades and transcription factors, such as AP-
1, HIF-1α, and NF-κB [2,3,16–18,26,51–55]. In addition, 
the ability of NO to rapidly react with the heme group of 
guanylate cyclase has been used as a message in activat-
ing downstream apoptotic cellular pathways [150,155].
Recent studies have focused on the role of H2O2 in regu-
lating apoptosis in several cell models. H2O2 is an oxidant 
that has been shown to trigger caspase activation and sub-
sequent apoptosis. H2O2-mediated caspase activation is 
dependent on the release of cytochrome c from the mito-
chondria, suggesting a key role for H2O2 in mitochondrial 
permeability and leakage [142,144,147,149,150,153].
The importance of dissecting the pathway from oxidative 
stress/redox signaling to apoptosis is not restricted to mod-
els in which cells are exposed to exogenous oxidants. 
Schematized pathways of apoptosis in the alveolar model 
and in the developing lung are given in Fig. 11. Intracellular 
oxidant production has been detected in cells incubated 
with a wide range of seemingly independent apoptotic 
agents, and some of these changes have been suggested 
to occur sufficiently early to be intricately involved in the ac-
tivation of apoptosis [160]. A recent example is p53-medi-
ated apoptosis, which has been proposed to occur through 
the increased transcription of pro-oxidant factors, thereby 
leading to caspase activation and apoptosis [156–159]. In-
terestingly, antioxidants and glutathione precursors con-
ferred a protective effect against ROS-mediated injury and 
subsequent apoptosis, implicating a critical role for ROS in 
initiating the death machinery [142–154].
It is becoming apparent, therefore, that the redox status of 
a cell can have complex and multilayered effects on apop-
tosis (Fig. 10B) [161]. It has been postulated that the mito-
chondria could be the principle sensors and that the 
release of mitochondrial factors such as cytochrome c is 
the critical event leading to caspase activation, and hence 
propagation of apoptosis [142–155]. The effectors of ap-
optosis, in particular the caspases, are redox-sensitive, and 
the cell must maintain a strict reducing environment for 
these effectors to function. By reasoning, therefore, it has 
been hypothesized that apoptosis cannot occur in cells 
subjected to excessive oxidative stress [144–161]. The 
ability of oxidants to inhibit caspase function need not be in-
compatible with oxidant-dependent caspase activation. 
First, low levels of oxidants appear sufficient for optimal 
caspase activation, suggesting specific signaling pathways 
rather than widespread oxidation. Second, the observed 
ability of cells to repair or replace oxidized caspases indi-
cates that the full complement of apoptotic effector mole-
cules can be regained at some time after the initial oxidative Respiratory Research   Vol 3 No 1   Haddad 
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Figure 11
Apoptosis signaling and pathways. (A) Schematic model for apoptosis pathways in the perinatal alveolar epithelium. Exposure to ascending ∆pO2
regimen and reactive oxygen species (ROS), a process referred to as chemioxyexcitation, triggers a signaling mechanism that could lead to either 
apoptosis or activation of NF-κB. NF-κB conveys a protective effect by amplifying Bcl-2 through the antagonism (anti-apoptotic) survival loop. 
Whereas thiols such as N-acetyl-L-cysteine (NAC) and γ-glutamylcysteinyl-ethyl ester (γ-GCE) promote the survival loop, sulfasalazine (SSA), a 
selective inhibitor of NF-κB, confers negative regulation favoring apoptosis. Glutathione depletion by L-buthionine-(S,R)-sulfoximine (BSO) upregu-
lates the expression of Bax and p53 through activation of the agonism (pro-apoptotic) death loop, an effect that is mimicked by pyrrolidine dithiocar-
bamate (PDTC). The likely 'executioners' implicated in apoptosis are the caspases, the final effectors in the death machinery. (B) Schematic model 
for apoptosis pathways in the perinatal developing lung. The transition from placental to lung-based respiration during the birth transition period con-
stitutes a potential signaling mechanism in the lung. This represents a relative hyperoxic shift, which allows the differential expression of signaling 
cofactors involved in apoptosis. The downstream pathway mediates suppression of Bcl-2 with pulmonary oxygenation, a phenomenon accompanied 
by down-regulating Bax. The major participant in regulating cell death ex utero is p53, which switches off the induction of Bcl-2 and rather predomi-
nates Bax in controlling apoptosis within the perinatal lung. This reinforces the presumption that signaling pathways mediating apoptosis in response 
to oxygenation in the developing lung are p53-dependent. The (+) sign indicated positive modulation (up-regulation) and (-) sign indicates negative 
modulation (down-regulation).Available online http://respiratory-research.com/content/3/1/26
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stress [145–161]. Elucidation of the pathways of oxidant-
induced apoptosis, therefore, may provide alternative ther-
apies to scavenging the initial oxidant in those systems 
where excessive oxidative stress and redox disequilibrium 
lead to inevitable cell death.
Regulation of cytokine/inflammatory signaling 
pathways in oxidative stress
Accumulating evidence has linked the pathogenesis of a 
variety of diseases to oxidative stress 
[8,12,22,27,33,37,40,41,142,145,162]. ROS, in particu-
lar, may contribute to alveolar capillary membrane perturba-
tions and development of lung injury [22,142–161]. 
Oxidative injury involves the modification of cellular macro-
molecules by toxic byproducts of oxygen metabolism. This 
condition often leads to cell death and/or the necrotic lysis 
of sensitive cells, resulting in the microvascular and alveolar 
injury typical of pulmonary oxygen toxicity [22,37,146]. 
Thus, dynamic variation in alveolar pO2 and its effect on 
cellular redox state may impose a direct role in modulating 
the pattern of gene expression and, thus, could be crucial 
in determining cellular fate and the inflammatory process 
regulated by cytokines [36–46,166,164].
Regulation of cytokines by ROS
ROS play a crucial role in the initiation and progression of 
pathophysiological conditions. The signaling mediators in-
volved in stress-induced lung injury are regulated, at least 
in part, by ROS that upregulate their secretion as part of 
antioxidant and immune defense mechanisms [154–164]. 
ROS-mediated pathways regulating cytokines are schema-
tized in 12A For example, bronchial epithelial cells produce 
soluble mediators on exposure to ROS, which stimulate the 
release of glycoconjugates in vitro[165–167]. In addition, 
ROS can induce the production of IL-6 and IL-8 in bronchi-
al and alveolar epithelial cells [36–46,168]. Furthermore, 
ROS can be released in response to a variety of stimuli, 
such as TNF-α and lipopolysaccharide [36–46,169] and 
they serve as intracellular signals for the activation of redox-
sensitive transcription factors [2,3,16–18,26,27,36–
46,164–170].
Among the mediators of oxidative stress, cytokines are of 
particular interest as they serve as signaling cofactors [37–
45]. IL-1β, for instance, is a pleiotropic cytokine produced 
in response to various stimuli. It acts as a modulator of re-
dox equilibrium [36–46]; moreover, there is substantial ev-
idence suggesting that, among other regulatory cytokines, 
IL-1β participates in transduction signals in oxidative injury 
via ROS and has stimulatory effects on regulatory tran-
scription factors mediating apoptosis [163–170]. IL-6 is re-
sponsive to inflammatory stimuli and oxidative stress [36–
46]. TNF-α, a stress-induced cytokine and a mediator of ox-
idative injury, has been implicated in the pathogenesis of 
respiratory distress [36–46,164–170]. Cytokines have 
also been shown to induce oxidative stress in several cell 
models [36–46].
Regulation of cytokines by redox equilibrium
The 'biomarkers' of oxidative stress, such as antioxidant in-
efficiency, redox disequilibrium and derivation of oxidant 
radicals, may arise from conditions other than hyperoxia 
(oxidizing signals) per se, such as hypoxia/re-oxygenation 
and cytokine-dependent processes [2,3,14,16–18,26,27]. 
In physiological conditions, the intracellular redox status of 
thiols is highly reductive. Glutathione, for example, is 
present in high concentrations in lung epithelial lining fluid 
and has been reported to maintain the integrity of the air-
space epithelium [171]. Glutathione depletion has been 
linked to the pathophysiology of idiopathic pulmonary fibro-
sis [171] adult respiratory distress syndrome [162,172] 
bronchopulmonary dysplasia [173] and cystic fibrosis 
[174].
Agents that induce the formation of ROS can affect redox 
homeostasis by upregulating antioxidant enzymes, particu-
larly glutathione peroxidase and enzymes involved in glu-
tathione recycling and biosynthesis [12,16,21,22,37–
41,115,116,164,169,170,175–177]. Furthermore, ROS 
signaling could be mediated by cytokines, whose participa-
tion in cellular pathways is modulated by redox status [35–
46,169–177]. Redox-mediated pathways regulating cy-
tokines are schematized in Fig. 12B. Conversely, cytokines, 
which themselves are mediators of oxidative stress, have 
the potential to alter redox equilibrium, thereby affecting 
glutathione/GSSG shuttling and recycling [35–46,169–
177].
The immunopharmacological potential assigned to glutath-
ione stems from established observations. IL-1-induced re-
sponses, for instance, occur through modulating the redox 
dynamic equilibrium [178]. In addition, ROS signaling reg-
ulating the transcription of IL-4 [179] IL-6, IL-8 [180] and 
TNF-α [181,182] is regulated by a thiol-dependent mecha-
nism. Interestingly, antioxidants and glutathione precursors 
have been shown to downregulate cytokine synthesis, acti-
vation and downstream processes [35–46,169–178]. 
Among the many agents that are used for repletion and de-
pletion of glutathione, NAC and L-buthionine-(S,R)-sulfox-
imine are, respectively, of particular importance as they 
exhibit antagonistic effects on a pro-inflammatory signal. 
NAC, an antioxidant and a glutathione precursor 
[13,14,19,40,41,111] has the ability to abrogate cytokine 
biosynthesis and ROS-mediated lung injury [35–46]. In 
contrast, L-buthionine-(S,R)-sulfoximine, which depletes 
glutathione by irreversibly inhibiting γ-glutamylcysteine syn-
thetase (the rate-limiting enzyme in the biosynthesis of glu-
tathione [39,41,48,103,104]), has the potential to enhance 
cytokine secretion by upregulating ROS [35–46,181,183]. 
It has been reasoned that a differential manipulation of glu-Respiratory Research   Vol 3 No 1   Haddad 
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Figure 12
Oxygen- and redox-mediated pathways regulating cytokines. (A) Schematic representation of the pathways leading to the generation of reactive oxy-
gen species (ROS) and their selective dismutation. A number of major cellular enzymes that defend against oxidative stress have been conserved 
through evolution. Superoxide (O2
-•) anion is metabolized via the dismutation reaction 2O2
-• + 2H+ → O2 + H2O2. The reaction is catalyzed by 
superoxide oxidoreductase dismutase (SOD), which is both a cytoplasmic enzyme that is constitutively expressed and a mitochondrial enzyme that is 
induced in response to oxidant stress. The H2O2 produced by the dismutation of O2
-• is converted by catalase (CAT) in peroxisomes to H2O and 
O2 and by glutathione peroxidase (GSH-PX) in the cytoplasm, at the expense of reduced glutathione (GSH). This leads to the formation of oxidized 
glutathione disulphide (GSSG) that is recycled back to GSH by glutathione reductase (GSSG-RD). H2O2 could be further converted by another 
pathway involving iron (Fe2+) into hydroxyl radical (•OH), an injurious ROS causing cellular damage. This iron-catalyzed reaction, known as the Fen-
ton-like reaction, is impeded by the iron chelator desferrioxamine (DSF), which is also capable of neutralizing the toxicity of •OH. (B) Schematic 
model of thiol regulation of chemioxyexcitation-induced cytokine secretion in the alveolar epithelium. The predominant form of intracellular glutathione 
is GSH, which is synthesized by γ-glutamylcysteine synthetase (γ-GCS). The molecules 2-oxothiazolidine-4-carboxylate (OTC), S-adenosyl-L-methio-
nine (SAM) and N-acetyl-L-cysteine are major precursors of cysteine, the rate-limiting substrate in the biosynthesis of GSH, a pathway which is 
selectively blocked by L-buthionine-(S,R)-sulfoximine (BSO). BSO upregulates the formation of intracellular ROS, which are major inducers of 
cytokine secretion. GSH is either rapidly exported, where the membrane-bound γ-glutamyl transpeptidase (γ-GT) degrades it into its subcellular 
components to be used for resynthesis, or is converted by oxidation to glutathione disulphide (GSSG) by glutathione peroxidase (GSH-PX) and its 
mimetic ebselen, at the expense of ROS (which are promptly detoxified to form peroxides, ROOH). The formation of GSSG and/or reduction of 
ROS downregulate the chemioxyexcitation-dependent cytokine release. GSSG is rapidly recycled back into GSH by glutathione reductase (GSSG-
RD), a pathway which is selectively blocked by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU). The block leads to accumulation of GSSG, which, 
along with pyrrolidine dithiocarbamate, a precursor of GSSG, downregulates the formation of ROS and abrogates the cytokine-dependent seque-
lae. Cytokines act as major participants in the pathophysiology and aggravation of the clinical symptoms of respiratory distresses (RD).Available online http://respiratory-research.com/content/3/1/26
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tathione homeostasis and shuttling antagonistically affects 
a proinflammatory signal. This has potential consequences 
for the treatment of respiratory distresses, where cytokines 
are recognized as major participants in pathophysiology.
Conclusion and future prospects
The molecular response to oxidative stress is regulated, in 
part, by redox-sensitive transcription factors [184–188]. 
The abrupt change in pO2, which accompanies the transi-
tion from placental to lung-based respiration, constitutes a 
mechanism that allows specific genetic regulation. Two 
transcription factors that form an integral part of the path-
ways augmented during this transition period are HIF-1α
and NF-κB, both of which are sufficiently tuned to govern a 
specific response in hypoxia and a relatively hyperoxic shift 
[184–191]. The perinatal epithelium responds to dynamic 
variations in pO2 by regulating their expression and activa-
tion with a unique responsiveness associated with upregu-
lating glutathione biosynthesis, as a major intracellular thiol 
bearing an antioxidant potential. Modulating the antioxi-
dant/pro-oxidant equilibrium by altering the glutathione/
GSSG redox potential evokes a genetic switch between 
HIF-1α and NF-κB, an effect uncoupled from the normal 
pattern that is followed with a prevailing pO2.
Analysis of the apoptotic potential prevailing under various 
∆pO2s reveals a novel differential expression of pro-apop-
totic and anti-apoptotic proto-oncogenes, a phenomenon 
that is redox-dependent and NF-κB-sensitive. Evidence has 
also been provided linking oxidative stress to a proinflam-
matory state, regulated by oxygen- and redox-sensitive cy-
tokines [183–192]. Thus, dynamic variation in pO2 and 
redox equilibrium regulates gene expression, apoptosis sig-
naling and the inflammatory process. This regulation bears 
potential consequences for screening emerging targets for 
therapeutic intervention and manipulation under conditions 
of oxidative stress that mimic those seen in clinical oxygen 
therapy.
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